Effect of Samarium on the Relief of Pain Due to Vertebral Metastases
Primary Purpose
Cancer, Metastasis, Pain
Status
Completed
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
Samarium (153SM)
Sponsored by
About this trial
This is an interventional treatment trial for Cancer focused on measuring Samarium, Kyphoplasty, Pain management, Bone metastases, Histologically proven malignancy in the primary site, Radiographic evidence of bone metastasis, Significant pain equal or more than score 5, Karnofsky Performance status >40, The patient must sign a study specific informed consent
Eligibility Criteria
Inclusion Criteria:
- The patient must be 18 years of age or older
- The patient must have histologically proven malignancy in the primary site (breast, prostate, or lung)
- The patient must have a radiographic evidence of bone metastasis, and this must have been performed within 8 weeks prior to enrollment in the study. Acceptable studies include plain radiographs, radionuclide bone scans, computed tomography scans, magnetic resonance imaging, and PET-CT scans.
- The patient must have an intact anterior wall of spinal canal
- The patient must have significant pain (score 6 or above,)which appears to be related to the radiographically documented metastatic vertebra(e) in concern, as measured by the "Visual Analog Scale"
- The patient must be surgically and medically accepted for vertebroplasty/kyphoplasty operation
- Karnofsky Performance status >40
- Expected life expectancy of 6 months or greater, as estimated by the physician in charge.
- The patient must sign a study specific informed consent prior to enrollment
Exclusion Criteria:
- Epidural soft tissue component
- Patients with vertebral metastases and with clinical or radiographic evidence of spinal cord or cauda equina impingement (effacement) or compression
- Inability to undergo anesthesia
- Hematologic primary malignancies Patients received systemic radiotherapy (89SR or 153SM)within 30 days prior to enrollmen
Sites / Locations
- New York Methodist Hospital
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Samarium (153SM)
Arm Description
Injection of Samarium (153SM)
Outcomes
Primary Outcome Measures
To determine the effect of intravertebral injection of Samarium on the relief of pain
Measuring the pain by the Visual Analogue Scale
Secondary Outcome Measures
Full Information
NCT ID
NCT00374751
First Posted
September 8, 2006
Last Updated
August 21, 2019
Sponsor
New York Presbyterian Brooklyn Methodist Hospital
1. Study Identification
Unique Protocol Identification Number
NCT00374751
Brief Title
Effect of Samarium on the Relief of Pain Due to Vertebral Metastases
Official Title
Phase I/II Study of the Use of Vertebral Intracavitary Cement and Samarium (VICS) for Painful Vertebral Metastases
Study Type
Interventional
2. Study Status
Record Verification Date
August 2019
Overall Recruitment Status
Completed
Study Start Date
May 2006 (undefined)
Primary Completion Date
January 2014 (Actual)
Study Completion Date
January 2016 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
New York Presbyterian Brooklyn Methodist Hospital
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Cancer cells may spread from the primary site to the vertebrae resulting in their deformity. The standard treatment for this case is removal of the cancer deposits in the vertebra and filling the induced cavity with a cement like substance.
The investigators are studying the effects (good or bad) of adding samarium (a radioactive substance) to the cement that is injected into the induced cavity.
Detailed Description
Protocol:
Patients with bone metastases will be identified and discussed in the weekly joint Neuroscience meeting held in Radiation Oncology Department.
If the patient is eligible to this study, the protocol will be offered to him/her. If the patient accepts; informed consent will be obtained.
The case will be scheduled jointly by Neurosurgeon and Radiation Oncologist.
Radiation physicist orders the radioactive samarium.
During the procedure:
Neurosurgical procedure ( kyphoplasty/vertebroplasty) is performed as standard using . mild general sedation and local anesthesia.
Once a cavity is identified in fluoroscopy, the trocar is secured. The volume and pressure of the kyphoplasty balloon are recorded.
According to standard practice; only the radiation team (Radiation oncologist, Physicist) is handling the radioactive material. All work is done under sterile conditions.
Two mCi. of Samarium is prepared after serial dilution steps under radiation precautions in the department of radiation oncology and material is transferred to OR.
0.5ml of "Head Cement" is administered first to act as a seal.
The Samarium is then introduced into the vertebral cavity using a 2-way valve by the Radiation Oncologist. Total of 0.5ml (Samarium+0.2ml radio opaque material)
The "Foot cement" (0.5 ml) is then introduced via the same 2-way valve into the vertebral cavity by the neurosurgeon to flush any remains of radioactivity in the system.
The two way valve is then removed and the rest of kyphoplasty/vertebroplasty is ensued as per their ordinary protocol.
Final volume of cement injected is recorded.
After securing the wound, all devices, syringes, gloves and basins used for handling the radioactive substance are collected in a "red bag" and stored by radiation safety officer in the hot lab. till full radioactive decay.
The room is scanned after patient's discharge, any spillage should be reported to radiation safety officer and normal procedures for environmental protection are ensued.
Post Procedure:
Normal neurosurgical recovery room protocol is employed. No radiation precautions needed.
Patient can be discharged home. No delays because of radiation precautions
Once patient is cleared, a nuclear imaging scan is obtained with Gamma camera. The ratio of uptake in the vertebra to background is calculated. Moreover, Full body scan is obtained to identify other areas of uptake if any.
A second nuclear imaging scan is done on the 4th day of the procedure (Two half Lives) to document significant decay and calculate dose.
MRI/CT scan of the area treated should be done in 4 weeks to assess outcome.
Clinical follow up is obtained at 2, 4 weeks and in 3 months. Careful pain score assessment is included in each time (Use Study Flow Sheet)
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cancer, Metastasis, Pain
Keywords
Samarium, Kyphoplasty, Pain management, Bone metastases, Histologically proven malignancy in the primary site, Radiographic evidence of bone metastasis, Significant pain equal or more than score 5, Karnofsky Performance status >40, The patient must sign a study specific informed consent
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
29 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Samarium (153SM)
Arm Type
Experimental
Arm Description
Injection of Samarium (153SM)
Intervention Type
Drug
Intervention Name(s)
Samarium (153SM)
Intervention Description
The Samarium is introduced into the vertebral cavity using a 2-way valve by the radiation oncologist. The cement is then introduced via the same 2-way valve into the vertebral cavity by the neurosurgeon.
Primary Outcome Measure Information:
Title
To determine the effect of intravertebral injection of Samarium on the relief of pain
Description
Measuring the pain by the Visual Analogue Scale
Time Frame
6 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
The patient must be 18 years of age or older
The patient must have histologically proven malignancy in the primary site (breast, prostate, or lung)
The patient must have a radiographic evidence of bone metastasis, and this must have been performed within 8 weeks prior to enrollment in the study. Acceptable studies include plain radiographs, radionuclide bone scans, computed tomography scans, magnetic resonance imaging, and PET-CT scans.
The patient must have an intact anterior wall of spinal canal
The patient must have significant pain (score 6 or above,)which appears to be related to the radiographically documented metastatic vertebra(e) in concern, as measured by the "Visual Analog Scale"
The patient must be surgically and medically accepted for vertebroplasty/kyphoplasty operation
Karnofsky Performance status >40
Expected life expectancy of 6 months or greater, as estimated by the physician in charge.
The patient must sign a study specific informed consent prior to enrollment
Exclusion Criteria:
Epidural soft tissue component
Patients with vertebral metastases and with clinical or radiographic evidence of spinal cord or cauda equina impingement (effacement) or compression
Inability to undergo anesthesia
Hematologic primary malignancies Patients received systemic radiotherapy (89SR or 153SM)within 30 days prior to enrollmen
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Hani Ashamalla, MD, FCCP
Organizational Affiliation
New York Presbyterian Brooklyn Methodist Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
New York Methodist Hospital
City
Brooklyn
State/Province
New York
ZIP/Postal Code
11215
Country
United States
12. IPD Sharing Statement
Learn more about this trial
Effect of Samarium on the Relief of Pain Due to Vertebral Metastases
We'll reach out to this number within 24 hrs